Association of Factor VII:C Levels with Environmental and Genetic Factors in Patients with Ischaemic Heart Disease and Coronary Atheroma Characterised by Angiography

Daniella M Heywood; Nicholas Ossei-Gerning; Peter J Grant

doi:10.1055/s-0038-1650546

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1996; 76(02): 161-165
DOI: 10.1055/s-0038-1650546

Original Article

Schattauer GmbH Stuttgart

Association of Factor VII:C Levels with Environmental and Genetic Factors in Patients with Ischaemic Heart Disease and Coronary Atheroma Characterised by Angiography

Authors

Daniella M Heywood

The Unit of Molecular Vascular Medicine, Division of Medicine, School of Medicine, University of Leeds, UK
Nicholas Ossei-Gerning

The Unit of Molecular Vascular Medicine, Division of Medicine, School of Medicine, University of Leeds, UK
Peter J Grant

The Unit of Molecular Vascular Medicine, Division of Medicine, School of Medicine, University of Leeds, UK

Abstract

PDF Download

Summary

Elevated Factor VII:C (FVII:C) levels are an independent risk factor for acute myocardial infarction. To examine the association between FVII:C levels, genetic and environmental factors in patients with a history suggestive of ischaemic heart disease, 270 patients were studied. FVII:C levels were significantly associated with the Msp I and promoter insertion polymorphisms. FVII:C correlated with environmental factors, and these correlations remained when analysed by genotype. In a multiple regression model, genotype, body mass index, cholesterol, triglycerides and gender remained as independent and significant predictors of FVII:C levels. There was no significant difference in FVII:C concentrations with severity of atheroma, or in patients with a history of myocardial infarction. These findings provide further evidence linking FVII:C with Msp I and promoter insertion genotypes and with environmental factors in established IHD, but suggest there is not a genotype-environment interaction or a relationship between FVII:C levels and severity of ischaemic heart disease.

PDF (348 kb)

References

References
1 Meade TW, Mellows S, Brovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick park heart study. Lancet 1986; 2: 533-537
2 Balleisen L, Schulte H, Assman G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; 2: 461
3 Meade TW, North WRS, Chakrabarti RR, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
4 Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2: 986-988
5 Heinrich J, Balleisen L, Schulte H, Assman G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-59
6 Broze Jr GJ, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255: 1242-1247
7 Fair DS. Quantification of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 1983; 62: 784-791
8 Hasselback R, Hjort PF. Effect of heparin on in vivo turnover of clotting factors. J Appl Physiol 1960; 15: 945-948
9 Green F, Kellener C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-546
10 Lane A, Cruickshank JK, Mitchell J, Henderson A, Humphries S, Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart diseases. Atherosclerosis 1992; 94: 44-50
11 Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-198
12 Saha N, Liu Y, Heng CK, Hong S, Low PS, Tay JSH. Association with factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. Arterioscler Thromb 1994; 14: 1923-1927
13 Meilahn E, Ferrell R, Kiss J, Temple A, Green F, Humphries S, Kuller L. Genetic determination of coagulation factor VIIc levels among healthy middle-aged women. Thromb Haemost 1995; 73: 623-625
14 Kario K, Narita N, Matsuo T, Kayaba K, Tsutsumi A, Matsuo M, Miyata T, Shimada K. Genetic determinants of plasma factor VII activity in the Japanese. Thromb Haemost 1995; 73: 617-622
15 Hey wood DM, Mansfield MW, Grant PJ. Factor VII gene polymorphisms, factor VII:C levels, and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 75: 401-406
16 Arbini AA, Bauer KA. Reduced plasma factor VII coagulant activity due to the Arg³⁵³Gln polymorphism in the factor VII gene results from defective secretion (abstract). Blood 1994; 86: 86
17 Marchetti G, Patracchini P, Papacchini M, Ferrati M, Bemardi F. A polymorphism in the 5 region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet 1993; 90: 575-576
18 Mariani G, Marchetti G, Arcieri P, Bemardi F. The role of factor VII gene polymorphisms in determining FVII activity and antigen plasma level variation (abstract). Blood 1994; 86: 86
19 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence of increased conversion of VII to VII in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249
20 Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1: 786-790
21 Miller GJ, Martin JC, Mitropoulos KA, Reeves BEA, Thompson RL, Meade TW, Cooper JA, Cmickshank JK. Plasma FVII is activated by postprandial triglyceridaemia irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-171
22 Van der Bom JG, Bots ML, Van Vliet HHDM, Hofman A, Grobbee DE. Factor VII coagulant activity is related to blood lipids in the elderly. The Rotterdam study. Fibrinolysis 1994; 8 (02) 132-140
23 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
24 Report of the joint international society and federation of cardiology/World health organization task force on standardization of clinical nomenclature. Nomenclature and criteria for diagnosis of ischaemic heart disease. Circulation 1979; 3: 607-608
25 Mansfield MW, Stickland MH, Carter A, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-736
26 Armitage P, Berry G. Statistical methods in medical research 2nd edition. Blackwell, Oxford 1987; 273-295
27 Buja LM, Willerson JT. The role of coronary artery lesions in ischaemic heart disease: Insights from recent clinocopathological, coronary arterio-graphic, and experimental studies. Hum Pathol 1987; 18: 451-461
28 Davies MJ, Thomas AC. Plaque fissuring: The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373
29 Bemardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb and Vase Biol 1996; 16: 72-76
30 Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cmickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipo-protein particles in middle-aged men. Atherosclerosis 1989; 76: 203-208
31 Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary intake and plasma FVII coagulant activity: a predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-277
32 Carvalho de Sousa J, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factor VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 940-944
33 Miller GJ, Martin JC, Mitropoulos KA, Reeves BEA, Thompson RL, Meade TW, Cooper JA, Cmickshank JK. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-171
34 Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 54: 721-723
35 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln₃₅₃ polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-127